Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Nvidia Corp (NVDA) vs Revvity Inc (RVTY) Price & Performance

Nvidia CorpTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

Nvidia Corp vs Revvity Inc — how do they compare? Nvidia Corp trades at $222.97 (market cap $5.45T), while Revvity Inc trades at $124.14 (market cap $14.18B). The key difference: Nvidia Corp is far larger — about 384.3× Revvity Inc's market cap, and Nvidia Corp pays the higher dividend (0.44%). Which is the better fit depends on your goals.

NVDARVTY
Market Cap
$5.45T$14.18B
Sector
TechnologyTechnology
52-Week High
$235.75$130.94
52-Week Low
$165.17$82.26
Enterprise Value
$5.43T$16.50B
Dividend Yield
0.44%0.22%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Nvidia Corp

NVIDIA (NVDA) trades at $225.73, down 2.01% over the past day, amid a broader tech sell-off. The stock maintains a bullish technical signal with strong moving average support, while oscillators are neutral. Fundamentally, the company reported robust revenue of $130.50B in 2025, with net income surging to $72.88B, reflecting a 55.84% profit margin. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.22 surpassing the $2.09 estimate. Analyst sentiment remains overwhelmingly positive, with a consensus price target of $344.10 implying significant upside.

Outlook: NVDA's leadership in AI chips and accelerating revenue growth present a compelling investment case, though risks include heightened competition and potential market saturation. The stock's current valuation metrics, such as a P/E of 28.54, appear reasonable given its growth trajectory. Institutional ownership trends and strong cash flow generation support long-term bullish sentiment, but investors should monitor execution risks and macroeconomic headwinds.

Revvity Inc

RVTY trades at $127.08, down 2.41% on the day, with a bullish technical signal from moving averages and strong support at $126. The company reported Q2 2026 EPS of $1.41, beating estimates, and raised its full-year outlook, driven by diagnostics strength and improved cash flow. Recent news includes the acquisition of Human Cell Design and the launch of the SuperFlex prenatal screening system.

Outlook is positive with 52% analyst buy ratings and a $135.25 consensus price target, implying ~6% upside. Risks include a premium valuation (P/E 61.1) and execution of growth initiatives. Strong institutional interest, such as Bank of New York Mellon's $78.77 million investment, supports confidence in the stock's trajectory.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Nvidia Corp

NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.

Read more on NVDA

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY